Nanoparticle-coupled topical methotrexate effectively inhibits inflammation and induces re-modeling in pre-clinical psoriasis

This project explores the efficacy of a novel skin-permeable MTX formulation, on murine and human xenotransplant models of psoriasis. Phenotypical and histological examinations of psoriatic tissue in these models have shown that the novel MTX can significantly suppress the inflammation. In order to understand the mechanistics of the new drug transcriptome of different treatment regimens (MTX-based, corticosteroid-based, and Vaseline control) will be compared to assess the pathological state of the skin. Transcriptomic changes of human skin on a xenotransplant model upon topical therapy was compared to psoriatic and normal-appearing skin from psoriasis patients

本研究探究了一种新型经皮吸收甲氨蝶呤（MTX）制剂在银屑病鼠类模型及人源异种移植模型中的药效。对上述模型中银屑病组织的表型与组织学检查结果显示，该新型甲氨蝶呤可显著抑制炎症反应。为阐明该新药的作用机制，本研究将对比不同治疗方案（甲氨蝶呤（MTX）组、糖皮质激素组、凡士林（Vaseline）对照组）的转录组数据，以评估皮肤病理状态。此外，本研究还将局部治疗后人源异种移植模型中人皮肤的转录组变化，与银屑病患者的银屑病皮损及外观正常皮肤进行对照比较。